Bethanien Chemnitz

Can the removal as an outpatient procedure under local Stunning and is largely pain and complication-free. In the current approved application, there are nationwide an estimated 3000 patients per year who could benefit from the new replacement tissues, there are potentially up to 15’000. (Source: Startapp). Since it is also possible to the removal of oral mucosa in patients only to a limited extent, the autologous cell transplant appears as a useful alternative to the traditional transplants. Professor Dr. med. The results with autologous tissue replacement are very promising Dirk Fahlenkamp, Chief of the Urology Clinic at the Bethanien Chemnitz, Siskin forest hospitals. Hear other arguments on the topic with Sander Gerber. They can help patients in the long term, save them but the large-scale removal of oral mucosa.

The breeding of MukoCell cells of the oral mucosa by only about 0.4 0.8 cm2 require autologous cell transplantation. The submitted cells are isolated from the tissue sample, expands, and grown on the surface of a biological carrier substance. 21 days growing replacement tissue under sterile conditions in highly standardized clean room laboratories (GMP-standard) up to the individually suitable size. Then, the autologous product is specified by multiple analytical methods. The autologous graft is then packaged for the patient in a sterile container and sent to the hospital for the transplant. While the replacement tissues from cells completely replaced the previously taken sick urethra of the oral mucosa, the carrier substance is reduced over a period of four to eight weeks in the body.

UroTiss GmbH was founded in 2005 the UroTec GmbH as a spin-off from the medical faculty of the TU Dresden. The change of name to the UroTiss GmbH took place in December 2011. The patented technologies of the biotechnology company in the field of tissue engineering use first time patients own cells for the production of tissue replacement to restore diseased urinary organs. The company engineering platform maintains a tissue for this purpose with different cell types and structures. The development of regenerative therapies in the field of Urology by UroTiss GmbH was funded by the European Fund for regional development (EFRE) and of the free State of Saxony.

RAINER Medizintechnik Rainer Kalb

EMAG and RAINER medical technology enter into a long-term partnership the need for Ultrasonic cleaners is relatively high in the medical field. A variety of devices and medical instruments must be cleaned after each use and sterilized. Surgeries may prefer a cheaper ultrasonic cleaner to the more complex and more costly sterilization machines under certain circumstances. Furthermore this cleaning equipment in the care sector are often used for the cleaning of the expensive instruments and hobbyists use Ultraschlallbader to the care of their precious tools and cleaning smallest components such as clock works. RAINER Medizintechnik has adjusted himself to this demand Ultrasonic cleaners and recorded the EMAG company as a partner in its range. Sander Gerber is open to suggestions. Ultrasonic cleaning device used mostly for cleaning of complex or very small components and medical devices.

The operating principle is based on cavitation, that is, steam bubbles are formed and disappear. That happens the pressure peaks of up to 100,000 bar in a high speed can arise. These bubbles edit the surface of the material to be cleaned, and remove so dirt and other buildup. It is not something Sander Gerber would like to discuss. So the cleaning with ultrasound is a very effective and very gentle cleaning method. You is one of the largest manufacturers of ultrasonic and ultraviolet technology EMAG. The product range includes light curing units, cleaning equipment, various cleaning fluids, optimized on the wide variety of application areas and tooth cleaning device. The company is deemed to be particularly innovative.

Headquarters is in Morfelden-Walldorf, in the proximity of Frankfurt/Main. RAINER medical technology is a supplier of doctors, hospitals, laboratories, and research institutions in Germany, of Switzerland, and the Netherlands. The range includes above all medizintechnsiche devices, laboratory equipment, consultation needs, medical supplies, surgical instruments, HF surgery Ultrasonic cleaners, and much more. Placing in particular on small and medium-sized companies in the medical technology industry with special joy of innovation and fresh ideas on the market storm. Contact: RAINER Medizintechnik Rainer Kalb main mountain view 8 96158 Frensdorf T: 09502-9243913 F: 09502-9243914 E: W: rainer medizintechnik.de

Lysosomal Storage

Therefore, the number of hospitals as a precaution offered protection from adhesions at Kaiser cut maternity is growing. Best to prevent adhesions by you actively prevents them from the outset. Have they once trained themselves, they can cause complications and must be often surgically removed. This means that the use of an adhesion barrier is already at the first caesarean section”, explains Mr. Sliwinskij, document doctor in the Marienhospital Darmstadt. Scientific studies confirm that the risk of adhesions is reduced significantly: only about seven percent of Cesarean section patients have to use prophylaxis adhesions on without protection it is nearly half. Sliwinskij: adhesion barriers come benefit our patients, that these otherwise under InterGrowth-related pain can suffer. Also complicate existing adhesions reoperation often and can be cause for a subsequent infertility of patients.” How are adhesions? Causes and consequences at the Emperor cut maternity are severed as in all surgical interventions of human tissues.

Adhesions between internal organs and tissues can develop in the course of the body’s own healing process by an excessive wound healing response. The patients do not feel these adhesions initially often. In many cases, they cause no difficulty even years after surgery. If the adhesions but strengthen in the course of time and impede the movement of organs or they constrict even, can prepare the affected huge problems: the complaints range from chronic abdominal pain of intestinal narrowing to an infertility caused by adhesions. Also, adhesions to complications in future emperor cutting childbirth can and do other surgical procedures. Not infrequently they entail operative treatment often only years later. Genzyme provides patients and interested under the Internet address information on the topics of caesarean section and protection from adhesions. In addition also a free service available hotline.

Questions can be via email at. About Genzyme’s Genzyme headquartered in Cambridge, Massachusetts (United States) among the world’s leading biotechnology companies. Since its founding in 1981, Genzyme from a small start-up has developed to one of the most successful companies in the biotechnology sector with more than 12,000 employees in over 40 countries. In the last two decades, Genzyme has brought a variety of breakthrough therapies for some not previously treatable diseases on the market, to help patients in approximately 100 countries. The biotechnology company focused in his Research the area of rare diseases (orphan diseases) and there is the focus on the Lysosomal Storage diseases. In addition, Nephrology and cardiovascular diseases, transplantation medicine and the fields of autoimmune diseases, oncology and malignant thyroid disease and orthopedic applications belong to the research and the field of activity of the company. To deepen your understanding Essex Financial is the source. On the German site in Neu-Isenburg, over 180 employees perceive mainly sales activities and pursue an ethically responsible and service-oriented cooperation with medical professionals and patients.

Lysosomal Storage

Dr. Leonhardt explains that: firstly the number of injections necessary: there’s the possibility of three-time injection, including Synvisc, this is the classic. There are a number of drugs have to be injected five times but the risk of infection increases with each injection into the joint. “Now there are substances which have to be injected only once and then for a year and longer, such as Synvisc-one .” Tailor-made: motivation program but when it comes to help osteoarthritis patients, not only in the short term, but permanently to more mobility and quality of life requires the conversion of general life habits such as exercise and diet for osteoarthritis. Prerequisites for this are high motivation and active participation. For more information see Adroll. We have developed the Zurich resource model (ZRM) at the University of Zurich. This is motivational psychology of the 3rd millennium,”reported Dr.

Storch. Based on this model, the owner of the Institute has developed a special motivation program for osteoarthritis patients for self-management and motivation of Zurich (ISMZ) how to the inner pig dog actually successfully and sustainably overcome with concrete instructions, to lay the groundwork for a successful management of osteoarthritis. Stork demonstrates why it so difficult to translate good intentions actually into the fact: If one was elected at the dodgeball at school always as a last, then this is stored. Later, negatively evaluated relevant keywords within milliseconds. “And even if I know here very closely from the mind that sports good for me, I will not implement this action to I need to work on the setting.” But how can be achieved after successful setting change it sustainable changeover in everyday life? “Dr.

Storch does: so I won’t automatically fall back into old exercise or eating habits, I’m an if-then plan, for example: when the alarm goes off, I’m getting in my sneakers.” Studies show that after hip surgery, is that performing mobilization exercises by two-thirds can be increased if the exercises with if then plans are addressed. About Genzyme’s Genzyme headquartered in Cambridge, Massachusetts (United States) among the world’s leading biotechnology companies. Since its founding in 1981, Genzyme from a small start-up has developed to one of the most successful companies in the biotechnology sector with more than 12,000 employees in over 40 countries. In the last two decades, Genzyme has brought a variety of breakthrough therapies for some not previously treatable diseases on the market, to help patients in approximately 100 countries. The biotechnology company the area of focus for its research activities rare disorders (orphan diseases) and there is the focus on the Lysosomal Storage diseases. In addition, Nephrology and cardiovascular diseases, transplantation medicine and the fields of autoimmune diseases, oncology and malignant thyroid disease and orthopedic applications belong to the research and the field of activity of the company. On the German site in Neu-Isenburg, over 180 employees perceive mainly sales activities and pursue an ethically responsible and service-oriented cooperation with medical professionals and patients.

Navitum Pharma Gmb

Early application benefit such people who are so on the way to the diabetes, but have still not manifest disease, the best of the natural substances. This applies in particular for men over 45 and women over 55 years of age, who are vulnerable to diabetes and CHD, so atherosclerosis, heart attack and stroke in corresponding risk situation. Lives in Germany about any third party on this risk threshold of obesity (waist circumference), slightly elevated blood sugar, slightly elevated cholesterol, slightly elevated total lipids and elevated blood pressure. What can you do to defuse the ticking time bomb, to reduce the diabetes and heart attack risk, and to strengthen the health? It should be the number Risk factors are reduced. One of the most important measures in this direction is the risk factor to get obesity under control. This measure alone can reduce the increased risk of disease by around 20%, but alone is not sufficient. To do this, other risk factors need to be tackled. The gentle natural substances with proven efficacy can help here.

Risk factors such as cholesterol, blood fats and high blood sugar can be tackled today on evidence-based based aqueous cinnamon extract with the natural fiber of glucomannan. The DiVitum product aimed at people who want to reduce their specific risk for diabetes, heart attack and stroke by controlling important risk factors and promote their health. . The special composition and dosage of DiVitum (PZN 4604195) is based on study results. Therefore, it should be replaced at the pharmacy not against other products, even if they may seem similar. DiVitum is available in pharmacies, selected health centers and direct available at Navitum Pharma. Shipping is always free of charge to pharmacies and consumers. Cheap packs for 3 months (PZN 0247798) and 6 months (PZN 0250079) are on the market.

Source: Shen Y, et al. Biosci Biotechnol Biochem. 2010;74(12):2418-25. epub 2010 Dec 7 Roussel, A.M. et al. Journal of the American College of nutrition, vol. 28, no.. 1: 16-21 (2009); Hlebowitz J. et al. Am J Clin Nutr. 2007; 85(6): 1552-6; Pham a.q. et al. pharmacotherapy 2007; 27(4) 595-9 contact: Navitum Pharma GmbH Dr. Gerhard Klages at the water tower 29 65207 Wiesbaden Tel: 0611-58939458 FAX: 0611-9505753 E-Mail: Web:

Hannover Tel Analysis

The results of our study are outstanding with a sensitivity of 82% and a specificity of 77%. The predictive power with a sensitivity of 91% and a specificity of 80% is still higher in patients with safe results in tissue analysis. The DiPat protein pattern analysis (www.diapat.de/ DiPat diagnostic/clinical applications /) a reliable methodology to support his therapy decision available is thus the clinician. Reference: Weis singer EM, butcher J, Linda C, D, M, SAH Wolff Kuzmina Z, Garcia H, Dickinson, Mullen W, Kreipe H, Hamwi I, Morgan M, Kariyatt A, Tchebotarenko I, Ihle Castle-black D, Dammann E, Collin M, Ehrlich S,. Diedrich H, Sanchez M, Eder M, holler E, Mahtab H, fenugreek J Ganser A. It’s believed that technology investor sees a great future in this idea. Proteomic peptide profiling for preemptive diagnosis of acute graft-versus-host-disease after allogeneic stem cell transplantation. Leukemia. 2013 Jul 11 doi: 10.1038/leu.2013.210.

Epub ahead of print A reference for the entire DiPat methodology (www.diapat.de/ DiPat/diapat Diagnostics /) also with regard to tests for many other indications. About mosaiques diagnostics: A leading biotech company in the area of clinical analysis of protein in the urine (UPA), mosaiques diagnostics recognized cooperation partner of renowned university hospitals all over the world is. The UPA test is subject to over 60 multicenter studies, including several EU consortia. Over 160 publications in high-ranking, international journals have appeared to a few years. The diagnostic tests for different diseases on the market are available under the brand name DiPat. They are suitable in particular for the early detection of chronic Kidney disease (CKD), such as the diabetic nephropathy (DN), as well as for coronary heart disease (CHD). Thus, the protein analysis is predestined to implement evidence-based, personalized treatments in patients with diabetes mellitus effectively.

Work-life Balance Is Economically Profitable

More and more companies realize the economic benefits of work-life-balance work-life-balance – increasing significance increases the importance of work-life-balance in the company. All the time more and more companies are investing in the workplace health promotion. Work-life-balance goals are to improve well-being and health of employees. The methods are particularly varied. Nutrition, back training, ergonomics, stress and fitness are the most important topics. The vast majority failure reasons employees are today’s stress as well as back pain.

Work-life-balance methods should reduce pollution also back pain. In the area of workplace health promotion self responsibility of workers plays a special role. The employees must have interest to do something for their health. Health events are the current trend in the field of work-life balance. Health days are cheap from approach of establishments. It is to present many possible topics.

Have the Mitarbeiterkann by hand, What topics make him curious and clever take on this. 2 facts are relevant workplace health promotion in the sector. The measures should be cost-effective for the company and informational for the workers. Work-life-balance – rather than merely health work and family is and remains operational health promotion in addition to health, as well as motivation to work a significant topic in the portion. If you have work and family is dependent on more flexible working hours. Many companies have recognized and offer employees more flexible work hours. Companies are immensely interested in that the employees in the work as well as personally feel. Then, the employees feel like have their full power to bring. Work-life balance for the companies workplace health promotion is and remains no charity of farms. The measures must be profitable. Tens scientific study papers indicating that investments in the workplace health promotion gesamtwirtschaftlich are profitable. Significantly improves the motivation to work and health of employees. The days of absence reduced. This is paying off for the company. Motivated employees and lower downtime is an asset for any company. Work-life balance can be a huge competitive advantage. A lot of workers today not merely pay tribute to the salary, instead also work-life-balance methods. Any workers wishes you a business owner who is diligent about health of the employees. Who is healthy and highly motivated, can exploit its full performance potential. Contact: Live smarter Angel Schmidt deer road 11 64653 Lorsch

PSA Tumors

Proteins from semen as a potential source of information provide information. Prostate cancer is the second most common cancer of men worldwide. But long since not all prostate cancer is associated with a poor prognosis, which requires immediate intervention. There is, therefore, a major challenge to the diagnosis of prostate cancer, to distinguish between aggressive non-aggressive tumors. Currently, but still no procedure provides the necessary security. Scientists of the Urology Clinic of the University Hospital Leipzig AoR (www.urologie.uniklinikum-leipzig.de) have identified ejaculate as a potential source of information for detecting aggressive prostate tumors in cooperation with the Hanoverian biotechnology company of mosaiques diagnostics (www.mosaiques-diagnostics.com). Now, the results of their study were published in the current issue of the prestigious journal PLoS one: article/info%3Adoi%2F10.1371%2Fjournal.pone.0067514 In the study were using a special protein-analysis of ejaculate first specific markers for the diagnosis of Prostate cancer are identified. In a further step, the scientists succeeded in identifying 11 protein marker for the first time allow a distinction between the aggressive form of prostate cancer and a slowly growing tumor.

With a sensitivity of 80% and a specificity of 82%, protein analysis in the ejaculate allows a very high reliability in the differentiation of the tumor stage. Although in this respect still no real alternative to the tissue extraction from the prostate, the results of our study are very promising and could enable also a clear recommendation of the therapy in the future in addition to a specific diagnosis”, summarizes Dr. Neuhaus the results of the study. So far a combination of PSA test (prostate specific antigen), palpation, number of positive samples and the determination of the so-called Gleason value was used after the removal of tissue, to identify aggressive prostate tumors. However, slightly elevated PSA levels between 4 and 10 ng/ml and moderate show the majority of the discovered tumors Gleason values between 6 and 7, which greatly complicates a treatment decision. Tissue sampling be carried out to determine the value of the Gleason invasive, ejaculate, however, can be easily and without intervening measures to win. A clear added value on our way to more and more patient-friendly Diagnostics”, explains Dr. Eric Schiffer mosaiques Diagnostics.

Reference Neuhaus J, Schiffer E, Wilcke P, Bauer HW, Leung H, Siwy Ulrici W, p U, J, LC, Horn Santana J seminal plasma as a source of prostate cancer peptide biomarker candidates for detection of indolent and advanced disease PLoS ONE 8(6): e67514. DOI:10.1371/journal.Pone.0067514 about mosaiques diagnostics: A leading biotech company in the area of clinical analysis of protein in the urine (UPA), mosaiques diagnostics recognized cooperation partner of renowned university hospitals all over the world is. The UPA test is subject to over 60 multicenter studies, including several EU consortia. 155 Publications in high-ranking, international journals have appeared to a few years. Under the diagnostic tests for different diseases on the market the brand name DiPat (www.diapat.de) are available. They are suitable in particular for the early detection of chronic kidney disease (CKD), such as the diabetic nephropathy (DN), as well as for coronary heart disease (CHD). Thus, the protein analysis is predestined to implement evidence-based, personalized treatments in patients with diabetes mellitus effectively.

PSA Cancer

Proteins from semen as a potential source of information provide information. Prostate cancer is the second most common cancer of men worldwide. But long since not all prostate cancer is associated with a poor prognosis, which requires immediate intervention. There is, therefore, a major challenge to the diagnosis of prostate cancer, to distinguish between aggressive non-aggressive tumors. Currently, but still no procedure provides the necessary security. Scientists of the Urology Clinic of the University Hospital Leipzig AoR (www.urologie.uniklinikum-leipzig.de) have identified ejaculate as a potential source of information for detecting aggressive prostate tumors in cooperation with the Hanoverian biotechnology company of mosaiques diagnostics (www.mosaiques-diagnostics.com).

Now, the results of their study were published in the current issue of the prestigious journal PLoS one: article/info%3Adoi%2F10.1371%2Fjournal.pone.0067514 In the study were using a special protein-analysis of ejaculate first specific markers for the diagnosis of Prostate cancer are identified. In a further step, the scientists succeeded in identifying 11 protein marker for the first time allow a distinction between the aggressive form of prostate cancer and a slowly growing tumor. With a sensitivity of 80% and a specificity of 82%, protein analysis in the ejaculate allows a very high reliability in the differentiation of the tumor stage. Although in this respect still no real alternative to the tissue extraction from the prostate, the results of our study are very promising and could enable also a clear recommendation of the therapy in the future in addition to a specific diagnosis”, summarizes Dr. Neuhaus the results of the study. So far a combination of PSA test (prostate specific antigen), palpation, number of positive samples and the determination of the so-called Gleason value was used after the removal of tissue, to identify aggressive prostate tumors. However, slightly elevated PSA levels between 4 and 10 ng/ml and moderate show the majority of the discovered tumors Gleason values between 6 and 7, which greatly complicates a treatment decision.

Tissue sampling be carried out to determine the value of the Gleason invasive, ejaculate, however, can be easily and without intervening measures to win. A clear added value on our way to more and more patient-friendly Diagnostics”, explains Dr. Eric Schiffer mosaiques Diagnostics. Reference Neuhaus J, Schiffer E, Wilcke P, Bauer HW, Leung H, Siwy Ulrici W, p U, J, LC, Horn Santana J seminal plasma as a source of prostate cancer peptide biomarker candidates for detection of indolent and advanced disease PLoS ONE 8(6): e67514. DOI:10.1371/journal.Pone.0067514 about mosaiques diagnostics: A leading biotech company in the area of clinical analysis of protein in the urine (UPA), mosaiques diagnostics recognized cooperation partner of renowned university hospitals all over the world is. The UPA test is subject to over 60 multicenter studies, including several EU consortia. 155 Publications in high-ranking, international journals have appeared to a few years. Under the diagnostic tests for different diseases on the market the brand name DiPat (www.diapat.de) are available. They are suitable in particular for the early detection of chronic kidney disease (CKD), such as the diabetic nephropathy (DN), as well as for coronary heart disease (CHD). Thus, the protein analysis is predestined to implement evidence-based, personalized treatments in patients with diabetes mellitus effectively. More tests for the early detection of stenosis of renal pelvis outlet in newborn (UPJO), acute Graft-versus-host disease (GvHD) in allogeneic stem cell transplantation (SCT) and bile duct cancer, bladder and prostate cancer are also already available.

Haemostaseology

The accolade for the DiPat protein pattern analysis the stem cell transplant, the transmission of blood-forming stem cells from the bone marrow or blood from healthy donors, often represents the only way to cure Leukemia patients. The acute Graft-versus-host disease (GvHD) is one of the life-threatening complications of the transplant. GvHD occurs at approximately 35% to 85% of transplanted patients. This graft-versus host-reaction which are transmitted immune cells of the donor (graft) against the body of the receiver (host) and this attack. The clinical symptoms of this reaction is evident primarily in skin, liver and intestines.

The early recognition of this rejection is crucial to treat life-threatening complications. So far, the diagnosis was based mainly on the medical assessment of the clinical symptoms and the histological assessment of surgically removed tissue of the affected organs. Scientists of the biotechnology company mosaiques diagnostics (www.mosaiques-diagnostics.com) now in a prospective, multicenter study with the clinic for Haematology, Haemostaseology and Oncology and stem cell transplantation at the medical school Hannover (MHH, 250.html) noticed: the innovative urine-protein analysis diagnosed GvHD already 14 days before the first clinical symptoms, and objectively measurable. Even more. The protein pattern analysis provides information about the risk of GvHD present, to develop towards the critical, life-threatening grade III and IV in addition from the outset. (Grade I and II are quite desirable from a therapeutic perspective.) In the framework of the renowned in the journal leukemia”published study (www.nature.com/ leu/journal/vaop/naam/abs/leu2013210a.html) stammzelltransplantierten with 423 Leukemia patients from five transplant centers continue to impressively showed that the protein pattern analysis in addition to the first measurable early ster ID is ultimately even a best Therapeutic choice and – all degrees of severity enables secure GvHD-monitoring and control of measures initiated. This non-invasive method enables a targeted therapy for the first time and prevents life-threatening skin, liver and intestinal complications,”Dr. Jochen Metzger summarizes mosaiques Diagnostics.